Selank + Semax
Experimental neuropeptide blend
A vendor blend whose combined efficacy, pharmacokinetics and interaction profile have not been established in controlled trials.
Mechanism
Combines proposed tuftsin-derived and ACTH-fragment signaling
Protocol studied in research
Study design shown in plain language. This is not a personal dosing recommendation.
Human evidence is absent, limited or not confirmatory
Anecdotal schedules are excluded because frequency of online repetition does not establish identity, safety, or a clinically meaningful dose.
Community-Reported Research Schedules
Descriptive community patterns are separated from clearly labeled trial-derived reference rows. Neither is personal dosing guidance.
| Research context or phase | Amount per administration | Schedule total | Frequency | Timing | Administration | Evidence level |
|---|---|---|---|---|---|---|
| Common intranasal blend schedule | 250/250–500/500 mcg | Variable by administrations | Once or twice daily | Morning and early afternoon | Intranasal | Community-reported |
Important: Repetition in online communities does not establish product identity, safety, effectiveness, or an appropriate exposure. Route-specific schedules, half-life estimates and reported cycle lengths are shown for comparison only.
Example Reconstitution Protocol
A hypothetical concentration calculation for literacy and review—not preparation, administration, or dosing instructions.
Assumes a labeled 1:1 vial containing 10 mg Selank + 10 mg Semax. At 10 mg total blend/mL, 500 mcg total equals 0.05 mL (5 units), and 1 mg total (500/500 mcg) equals 0.10 mL (10 units). This arithmetic does not establish an injectable schedule.
Community reference: Common 10 mg + 10 mg blend presentationImportant: Vial strength, diluent identity, compatibility, sterility, stability and beyond-use time are product-specific. Never infer them from this arithmetic example. Use manufacturer, pharmacy, study, or licensed-clinician instructions for an actual preparation.
Cycle & Supplies Planning
Phase-by-phase cycle math showing how long a vial lasts and the estimated supplies required.
No single, consistently reported subcutaneous amount-and-frequency pair is available for a responsible automatic supply calculation.
Planning boundary: These are arithmetic examples based on the displayed research schedule—not personal dosing or purchasing instructions. Confirm product format, compatibility, route, sterility, storage, and discard timing independently. U-100 units measure liquid volume, not potency.
Safety signal
Evidence for either component cannot be assumed to validate the mixture.
Reported doses describe either a specific study or an unverified community pattern. Neither is personal medical guidance.